New Celution® System Patent, Cytori (CYTX)
CYTX received US Patent No. 7,771,716 (“716” patent) for Celution® System based methods of treating musculoskeletal disorders such as spinal disc disease.
The 716 patent covers the therapeutic use of adipose-derived stem and regenerative cells (ADRCs) for promoting repair and regeneration of the spinal disc and formation of bone, cartilage, skeletal muscle, tendon and ligaments.
- The patent builds upon the CYTX’s patent strategy covering methods of obtaining and processing of stem and regenerative cells from adipose tissue. The 716 patent is the 10th US patent issued with 14 international patents and more than 100 patent applications pending worldwide relating to devices, methods and uses of adipose-derived stem and regenerative cells.
The Bottom Line: The 716 patent includes 61 dependent claims covering site of cell delivery, additives to the Celution® System output, surgical implants, scaffolds, spinal fusion devices for use with the Celution® System output, cell culture and differentiation of the Celution® System output as well as a variety of disaggregation agents and device configurations. CYTX’s Celution® System automates the extraction of the stem and regenerative cells naturally occurring in adipose tissue for both clinical and research use.
- In 12/08, Cytori presented 12 month preclinical results indicating that ADRCs can promote repair of damaged spinal discs. In a large animal model, ADRC-treated discs showed a significant increase in disc tissue density and disc-specific extracellular matrix components.
